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ABSTRACT
Objectives: Non-steroidal anti-inflammatory drugs
(NSAIDs), proton pump inhibitors (PPIs), low-dose
aspirin and statins may decrease the risk of
oesophageal adenocarcinoma (OAC) among patients
with Barrett’s oesophagus (BO). However, previous
studies did not adequately address bias and
confounding. Our objective was to estimate the risk of
OAC among patients with BO exposed to NSAIDs,
statins and PPIs.
Design: Case–control study nested within a BO
cohort.
Setting: Two primary care databases (the UK and the
Netherlands (NL)).
Participants: Cases were adults ≥18 years of age
with OAC or high-grade dysplasia (HGD) diagnosis
≥1 year after BO diagnosis. Controls were matched on
age, sex, year of BO diagnosis and database.
Exposure: Drug use was assessed from BO diagnosis
until matching date.
Outcome measure: Adjusted ORs with 95% CI were
calculated by conditional logistic regression.
Results: Within the BO cohort (n=15 134), 45 OAC
(UK: 40, NL: 5) and 12 HGD cases (NL: 12) were
identified. ORa for OAC during NSAID use was 1.2
(95% CI 0.6 to 2.5) and during statin use for >3 years
0.5 (95% CI 0.1 to 1.7). When including HGD cases
(n=57), ORa for NSAID use was 0.9 (95% CI 0.5 to
1.8) and for statin use >3 years 0.5 (95% CI 0.1 to
1.7). Higher doses of statins showed lower estimates
for OAC and HGD, though not statistically significant.
Low-dose aspirin and PPIs did not significantly
decrease the risk of OAC and HGD.
Conclusions: In this population-based nested case–
control study, use of NSAIDs, PPIs, low-dose aspirin
or statins did not reduce the risk of HGD and OAC
among patients with BO. These findings indicate that
for an unselected group of patients with BO
chemoprevention by use of drugs to reduce
progression to HGD and OAC should not be directly
considered as routine care.
INTRODUCTION
Barrett’s oesophagus (BO) is a premalignant
condition in which the squamous epithelium
of the oesophagus is replaced by metaplastic
columnar epithelium.1 BO is considered a
consequence of prolonged gastro-oesophageal
reﬂux2 and is the most important risk factor
for development of oesophageal adenocarcin-
oma (OAC) via a stepwise pathway of low-grade
and high-grade dysplasia (HGD). It is esti-
mated that the risk of OAC is increased by
approximately 30–125-fold in persons with
BO,3 and occurs in a small proportion of
patients with BO yearly.4 Endoscopic surveil-
lance for BO is therefore recommended.2
In recent decades, the incidence of BO
increased, accompanied by a marked increase
Strengths and limitations of this study
▪ Within a population-based cohort of incident
Barrett’s oesophagus (BO) patients derived from
two European countries, and applying a common
study protocol and drug exposure definition, the
risk of development of oesophageal adenocarcin-
oma (OAC) was estimated during use of several
drugs individually and concomitantly.
▪ We were able to minimise certain biases, for
instance, due to availability of drug prescription
data recall bias was avoided and by using a
population-based approach selection bias was
minimised.
▪ The small number of OAC cases that was identi-
fied limited the power for the duration analyses.
▪ We did not have detailed pathology information on
the Barrett segment length or grade of dysplasia at
cohort entry for every BO cohort member in both
countries. This may have resulted from including
patients with a short segment BO who may be at
lower risk of developing high-grade dysplasia and
OAC at the outset.
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in OAC incidence in the USA and Western Europe.5 6
However, estimates of OAC incidence among patients with
BO vary substantially.7–10 Generally, gastrointestinal
cancers account for 25% of all cancers and approximately
4.9% of all deaths worldwide.11 Death rates of most
cancers decreased in recent years in contrast to the 3%
increase in death rates of all oesophageal cancers (squa-
mous cell carcinoma as well as adenocarcinoma) among
males.11 The age-standardised mortality rate for oesopha-
geal cancer overall is 5.1/100 000 persons.6 The need for
effective prevention of oesophageal cancer, in general, is
therefore warranted, particularly given the low 5-year sur-
vival rate of 13–17%.12
Several studies reported that use of non-steroidal anti-
inﬂammatory drugs (NSAIDs), low-dose aspirin, statins
and proton pump inhibitors (PPIs) may decrease the risk
of OAC among patients with BO.13–21 However, these
studies were based on small, selected samples of OAC
cases. PPIs are considered standard care for symptom
relief in patients with BO, thus it was suggested that PPIs
may decrease the risk of progression to HGD or OAC.20 In
contrast, other studies showed an increase in risk of OAC
with PPI use, probably because the underlying treatment
indication may be a risk factor for OAC rather than that
PPIs being harmful for OAC among patients with BO.15 22
Nevertheless, one cannot directly assume that PPIs, which
are efﬁcacious for treatment of erosive oesophagitis, will
also be beneﬁcial in the pathway from BO to OAC devel-
opment. Two meta-analyses both including nine observa-
tional studies showed that the risk of oesophageal cancer14
and HGD/OAC23 among those who frequently use
NSAIDs or aspirin was signiﬁcantly lower compared with
never users.14 However, studies included in the earlier
meta-analysis did not speciﬁcally include patients with BO.
A pooled analysis on individual patient data conﬁrmed the
signiﬁcant reduction in risk of OAC in patients with BO
with NSAID prescriptions.24 Two case–control studies
observed an association between use of NSAIDs15 and
statins,15 25 and the risk of OAC among patients with BO.
Generalisation and extrapolation of results from the latter
studies to the general population is, however, difﬁcult as
both studies were performed in US veterans.15 25
Additionally, there was no adjustment for important risk
factors of OAC progression such as alcohol use and
smoking.15 Nevertheless, a recent systematic review and
meta-analysis showed a risk reduction in development of
oesophageal cancer in general and OAC among patients
with BO who took statins.26
Causality of an apparent association is generally sup-
ported by a dose–duration relationship.27 However,
studies to date neither reported a clear exposure deﬁn-
ition free of recall bias13 16 24 nor conducted dose–dur-
ation analyses. Finally, concerns have been raised about
publication bias of these studies on chemoprevention of
OAC in patients with BO.18
Thus, to what extent NSAIDs, low-dose aspirin, statins
and PPIs may reduce the risk of OAC among patients
with BO in clinical practice remains unknown.
Therefore, we conducted a matched case–control study
to evaluate the risk of OAC among patients with BO
associated with use of NSAIDs, low-dose aspirin, statins
and PPIs.
MATERIALS AND METHODS
DATA sources
Two European population-based general practice registries
served as data sources: (1) The Health Improvement
Network (THIN) from the UK (1996–2011)28 and (2) the
Integrated Primary Care Information database (IPCI)
from the Netherlands (NL, 1996–2012).29 Both databases
contain prospectively collected data that represent real-life
practice. In the UK and in NL, all citizens are registered
with a general practitioner (GP), who acts as a gatekeeper
to secondary and tertiary medical care. THIN collects
anonymised data on more than 3 million active patients
from over 400 participating general practices, IPCI con-
tains over 1.5 million active patients from 340 practices.
For each individual patient all relevant medical informa-
tion, from primary and secondary care, as well as add-
itional information, including demographics and drug
prescriptions, is documented in the medical record. Both
data sources comply with European Union guidelines on
the use of medical data for research.
THIN employs the READ clinical terminology system
for coding medical diagnosis and symptoms,30 whereas
IPCI uses the International Classiﬁcation for Primary
Care (ICPC).31 Information on drug prescriptions is cap-
tured in THIN with the Multilex product dictionary and
British National Formulary (BNF) codes, whereas in
IPCI, information on drug prescriptions is coded accord-
ing to the WHO’s Anatomical Therapeutic Chemical
(ATC) classiﬁcation.32 Identiﬁcation of the source and
study population has been described previously.10
Source population
The source population consisted of all patients aged
≥18 years who contributed data to the database between
1 January 1996 and 31 December 2011 (THIN) or
March 2013 (IPCI). At least 1 year of available data prior
to study entry were required to assess patient’s medical
history for exclusion criteria and risk factors. Follow-up
started on 1 January 1996, or the date of reaching
18 years of age, or the date that 1 year of valid data were
accrued within the database, whichever came later.
Follow-up ended on the date of occurrence of study
outcome (OAC), date of transfer out of the GP’s prac-
tice, death, or last data drawn, whichever was earliest.
Definition of BO
Patients with BO were identiﬁed using diagnosis codes;
in THIN using corresponding READ codes (online sup-
plementary appendix table 1).30 In IPCI, each potential
BO case was manually validated to conﬁrm the histo-
logical diagnosis of BO and the date of ﬁrst diagnosis or
mentioning of BO in the clinical record. Patients were
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excluded if they had a history of oesophageal cancer
anytime before BO diagnosis and if they had a history of
gastric cancer within 6 months after BO diagnosis. In
IPCI, we could utilise free text from the medical record
to assess the Barrett segment length and grade of
dysplasia.
Definition of OAC
In THIN, OAC cases were identiﬁed by READ codes
(online supplementary appendix table 1). In IPCI, all
patients with a record of ICPC codes D77.1 (malignant
neoplasia of the oesophagus) and D77.0 (malignant
neoplasia of the digestive tract—not speciﬁed), or with a
record from free text search including word combina-
tions of ‘oesophagus’, ‘cancer’, ‘carcinoma’, ‘malig-
nancy’ or ‘neoplasia’, were identiﬁed. Similar to BO, all
potential cases were manually validated for conﬁrmation
of the OAC diagnosis, date of ﬁrst diagnosis and the
type of carcinoma (squamous cell carcinoma, adenocar-
cinoma, or other types of carcinoma). Early cancer
(HGD) was identiﬁed in IPCI also, but could not be
assessed in THIN.
We only considered incident HGD or OAC cases: that
is, if the date of diagnosis occurred after inclusion into
the BO cohort and was at least 12 months after BO diag-
nosis. Cases occurring within 1 year from BO diagnosis
were considered to be already existent at BO diagnosis
date and in relation to the BO diagnostic work-up.
Cases and controls selection
Two nested case–control studies were conducted asses-
sing the risk of OAC for use of four drugs (NSAIDs,
PPIs, statins and low-dose aspirin); one including only
OAC cases and a second case–control study including
HGD cases from IPCI as well.
Cases were adults diagnosed with OAC ≥12 months
after BO diagnosis, because cases occurring within
1 year of BO diagnosis were considered to be existent
and related to BO diagnostic work-up (eg, missed OAC
at BO diagnosis). Index date was deﬁned as date of ﬁrst
reporting of OAC diagnosis during follow-up. Controls
were members of the incident BO cohort who did not
develop OAC up to matching date. Controls were
matched by incidence density sampling on age
(±5 years), sex, year of BO diagnosis (±1 year) and data-
base. We matched on year of BO diagnosis in order to
account for any inﬂuence of guideline changes in endo-
scopic surveillance over calendar time.
Drug exposure
Drug exposures of interest included four drug groups:
NSAIDs, PPIs, statins and low-dose aspirin. They were
assessed in terms of outpatient prescriptions for NSAIDs
(including high-dose aspirin, ie, >325 mg/day), PPIs,
statins and low-dose aspirin (up to 325 mg/day) from
BO diagnosis until OAC diagnosis. In order to compare
the OR of NSAIDs, PPIs and statins to other drugs, we
considered another group of medications, which served
as control. Antidepressants (selective serotonin re-uptake
inhibitors (SSRIs)) are currently not known to be either
positively or negatively associated with OAC.
Duration of prescriptions was calculated based on the
prescribed quantity and dosing regimen. As the most
likely preventive effect of drugs on cancer progression is
through a cumulative mechanism, we calculated all dur-
ation and deﬁned daily dose (DDD) values from date of
BO diagnosis until index date. Duration was classiﬁed
according to never use (reference category), cumulative
use of less than 1 month, between 1 and 12 months,
>12 months (or if applicable 1–2 years; 2–3 years and
>3 years). Considering that PPIs are indicated as treat-
ment for patients with BO, duration was classiﬁed as
0–6 months (reference category), 6–12 months, 1–2 years
and >2 years. Dose of exposure was classiﬁed using the
ratio of prescribed daily dose compared with DDD using
quartiles into categories (<0.8, 0.8–1.2, ≥1.2 DDD per
day). As there is no DDD for low-dose aspirin, dose ana-
lysis was not performed for use of low-dose aspirin.
Potential confounders
We considered as potential confounders: concurrent
diagnosis of oesophagitis or gastritis within 1 year before
BO diagnosis; hiatal hernia; smoking habits (non-
smoker, ex-smoker, current smoker) and alcohol abuse
(never, current, past).
Statistical analyses
Baseline characteristics of cases and controls were
described per database and compared using univariate
conditional logistic regression.
To estimate the risk of HGD and OAC among patients
with BO, matched and adjusted ORs (ORa) with 95%
CIs were calculated using conditional logistic regression
for both databases separately and as a pooled analysis on
patient-level pooled data.
Potential confounders were included in the adjusted
analysis (ORa) if they resulted in a change of more than
10% of the initial estimate. Time since BO diagnosis was
forced into the adjusted model.
Subsequent analyses included dose–duration analyses.
The risk of OAC and HGD–OAC was also assessed for con-
comitant use of NSAIDs, low-dose aspirin, statins and/or
PPIs. Use of PPIs only was considered as reference cat-
egory considering that PPIs are standard therapy for BO.
All analyses were performed using SAS V.9.2 (Cary,
North Carolina, USA).
Power calculation
Given an exposure prevalence of NSAIDs of 30%, statins
of 22% or 36%, PPIs of 87% or 52% and low-dose
aspirin of 25% among controls and a correlation of 0.5
between exposed and unexposed patients we have 80%
power (with a type 1 error of 5%) to detect a true OR of
OAC of 0.34 for NSAIDs, around 0.38–0.40 for statins,
around 0.32–0.45 for PPIs and 0.29 for low-dose aspirin,
which would be in concordance with previous studies.
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RESULTS
Study population
From the source population of 7 570 765 patients in the
UK and 1 496 276 patients in NL we identiﬁed 13 696
and 1438 incident BO cases, respectively. Men
accounted for 63% (the UK) and 62% (NL) of patients
with BO. Mean age at BO diagnosis was 64.8 (SD 13.8)
years in the UK and 61.2 (SD 13.4) years in NL.
In the UK, we identiﬁed 40 incident OAC cases within
the BO cohort (0.3%) to whom we could match 656 con-
trols. Median number of controls per case was 17 (IQR
9–23). In NL we identiﬁed ﬁve incident OAC cases among
the BO cohort (0.3%). These were matched to 76 control
subjects, with a median of 5 controls per case (IQR 4–6).
In addition, we identiﬁed 12 HGD cases, resulting in a
second case–control set of 17 cases (5 OAC+12 HGD)
matched to 753 controls (median 44 controls; IQR 6–61).
Figure 1 shows a ﬂowchart of the study population. Table 1
provides baseline characteristics of cases and controls. In
the UK, a larger proportion of cases had a body mass
index (BMI) over 25 kg/m2; 68% of cases and 59% of con-
trols. In NL, the BMI of only one case within 1 year of
OAC diagnosis was available (21.3 kg/m2). Controls had a
mean BMI of 28.7 kg/m2 (SD 4.7) in NL. Presence of
oesophagitis or gastritis at time of BO diagnosis was more
often seen in controls than in cases. In the UK, a hiatal
hernia was more often present among cases, whereas the
opposite was found in NL. In the UK, OAC cases were
more likely to be current smokers than controls (OR 3.3;
95% CI 1.4 to 8.0), as seen in NL, though not signiﬁcantly.
Mean time from BO diagnosis until OAC diagnosis was 4.2
(SD 2.5) years in the UK and 3.5 (SD 0.8) years in NL.
Drug exposure
Table 2 provides characteristics of drug use from BO
diagnosis until index date for cases and controls per
database. Statins were used by 30% and 0% of OAC
cases; and by 36% and 22% of controls in the UK and
NL, respectively. PPIs were used by OAC cases for a
mean of 4.1 years (the UK) and 2.3 years (NL), and by
controls for 2.9 years (the UK) and 1.9 years (NL).
SSRIs were used by 12.5% of OAC cases in the UK for a
mean duration of 1 year, and by 7.6% of controls for a
mean duration of 1.7 years. Low-dose aspirin was used
by 26% of patients with BO in the UK and 6% of
patients with BO in NL.
Risk of oesophageal adenocarcinoma
To estimate the risk of OAC with use of NSAIDs, PPIs,
statins and low-dose aspirin, a nested case–control study
was conducted. From the adjusted model, on patient-
level pooled data, exposure to NSAIDs and PPIs did not
provide a signiﬁcant decrease in the risk of OAC
(table 3); for statins a non-signiﬁcant effect was seen
(ORa 0.7; 95% CI 0.4 to 1.5). This was seen in both data-
bases separately as well (data not shown).
For NSAID use, ORs ranged between 1.1 and 1.4 for
all duration categories; regarding dose-analysis, no differ-
ence in risk was found between higher and lower
dosages (table 4). Although not signiﬁcant, a dose–dur-
ation–response was seen for statins, with lower OR for
longer duration of use compared with non-use of statins.
Statin use ≥1.2 times higher compared to the recom-
mended DDD resulted in an OR of 0.7 (95% CI 0.2 to
2.3). For PPIs an increase in OR was seen with pro-
longed duration, in the matched and in the adjusted
analyses. PPIs used at highest dose showed an OR for
HGD–OAC of 0.9 (95% CI 0.3 to 2.3). The ORs varied
for duration categories of SSRIs. No dose–response was
seen for SSRI use. Use of low-dose aspirin provided ORs
below 1 for OAC for matched and adjusted analysis,
when considering the exposure at any time between BO
diagnosis and OAC diagnosis; however, the 95% conﬁ-
dence limits still included the 1. When considering
Figure 1 Flowchart of Barrett’s
oesophagus and oesophageal
adenocarcinoma cases in the UK
and the Netherlands. BO,
Barrett’s oesophagus; OAC,
oesophageal adenocarcinoma;
HGD, high-grade dysplasia;
THIN, The Health Improvement
Network; IPCI, Integrated Primary
Care Information; PYs, person
years.
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Table 1 Baseline characteristics of OAC cases and HGD cases in the UK and the Netherlands
The UK The Netherlands HGD–OAC
OAC case
N (%) Control N (%) OR (95% CI) p Value
HGD–OAC
Case N (%)
HGD–OAC
control N (%) OR (95% CI) p Value
Total 40 (100) 656 (100) 17 (100) 753 (100)
OAC 5 (29.4)
HGD 12 (70.6)
Sex
Male 33 (82.5) 597 (91) 11 (65) 524 (70)
Female 7 (17.5) 59 (9) 6 (35) 229 (30)
Mean age at index date (SD) 71.2 (10.4) 70.2 (9.0) 68.8 (8.2) 66.4 (8.8)
Age group (years)
<50 1 (2.5) 14 (2.1) 0 (0) 17 (2.3)
51–65 8 (20) 149 (23) 6 (35) 338 (45)
66–80 25 (62.5) 434 (66) 10 (59) 364 (48)
>80 6 (15) 59 (9) 1 (5.9) 34 (4.5)
BMI (kg/m2) mean (SD) 27.7 (4.1) 26.9 (4) 1.1 (1.0 to 1.1) 0.210 28.9 (6.8) 26.4 (7.4) 1.1 (0.9 to 1.3) 0.500
BMI categories
18–25 10 (25) 202 (31) 1 (5.9) 85 (11)
<18 0 (0) 7 (1.1) – 0.989 0 (0) 22 (2.9) – 0.997
>25–30 19 (47.5) 269 (41) 1.5 (0.7 to 3.3) 0.329 2 (12) 156 (21) 1.3 (0.1 to 14.7) 0.995
>30–35 7 (17.5) 89 (14) 1.8 (0.7 to 5.0) 0.246 0 (0) 73 (9.7) – 0.995
>35 1 (2.5) 31 (4.7) 0.8 (0.1 to 7.0) 0.866 1 (5.9) 14 (1.9) 6.1 (0.3 to 112.1) 0.993
Missing 3 (7.5) 58 (8.8) 1.0 (0.3 to 3.8) 0.992 13 (76) 403 (54) 2.0 (0.3 to 16.5) 0.994
Oesophagitis at BO diagnosis
No 39 (97.5) 629 (95.9) 14 (82) 525 (70)
Yes 1 (2.5) 27 (4.1) 0.6 (0.1 to 4.7) 0.633 3 (18) 228 (30) 0.5 (0.1 to 1.8) 0.299
Gastritis at BO diagnosis
No 38 (95) 621 (94.7) 13 (76) 582 (77)
Yes 2 (5) 35 (5.3) 1.2 (0.3 to 5.2) 0.808 4 (24) 171 (23) 1.5 (0.5 to 4.9) 0.516
Hiatal Hernia at BO diagnosis
No 33 (82.5) 579 (88.3) 8 (47) 268 (36)
Yes 7 (17.5) 77 (11.7) 1.7 (0.7 to 4.0) 0.259 9 (53) 485 (64) 0.7 (0.2 to 2.0) 0.487
Excessive alcohol use
Never 17 (42.5) 370 (56) Ref 17 (100) 713 (94.7) – 0.991
Current 22 (55) 276 (42) 2.0 (1.0 to 3.0) 0.048 (0) 40 (5.3)
Past 1 (2.5) 10 (1.5) 2.8 (0.3 to 23.4) 0.345
Smoking
Never 14 (35) 322 (49) Ref 9 (53) 380 (50.5) Ref
Current 9 (22.5) 70 (11) 3.3 (1.4 to 8.0) 0.009 8 (47) 373 (49.5) 1.5 (0.5 to 4.5) 0.443
Past 17 (42.5) 264 (40) 1.7 (0.8 to 3.7) 0.155
Index year
1998 1 (2.5) 7 (1.1) 1 (5.9) 5 (0.7)
2000 1 (2.5) 12 (1.8) 1 (5.9) 4 (0.5)
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duration analysis, the adjusted model provided for the
prolonged duration of use (>1 year) an OR of 0.9 (95%
CI 0.4 to 2.1).
Concomitant use of drugs of interest did not decrease
the risk of OAC (table 5) compared with use of PPIs
only, probably due to the smaller number of cases.
Risk of high-grade dysplasia or oesophageal
adenocarcinoma
In NL, we were able to retrieve HGD cases as well. When
including these in the case deﬁnition, the effects were atte-
nuated but in the same direction as the case–control study
including OAC cases only. There was no signiﬁcant
decrease in the risk of HGD–OAC for exposure to
NSAIDs, statins, PPIs and low-dose aspirin in the adjusted
analysis (table 3). For NSAIDs, the OR increased with use
of higher dosages (table 4). Again, for statins, a duration–
response relationship with the longest duration yielding
the lowest ORa (0.5; 95% CI 0.1 to 1.7) and an inverse
association with increasing dose was observed, though
none signiﬁcant. For low-dose aspirin, PPI and SSRI use,
no dose–response effects were shown.
The risk of HGD–OAC was 13% lower for concomitant
use of NSAIDs+PPIs (ORa 0.9; 95% CI 0.3 to 2.2; table 5).
None of the associations were statistically signiﬁcant.
DISCUSSION
In this population-based case–control study nested
within a cohort of patients with BO, statin use may
decrease the risk of OAC and HGD by up to 50%. PPIs
did not reduce the risk of HGD and OAC, however, only
when used at highest dose (eg, at least 1.2 times the
recommended daily dose) a non-signiﬁcant reduction
may be present. In this unselected group of patients
with BO, use of low-dose aspirin or NSAIDs was not asso-
ciated with a decrease in risk of OAC. This is the ﬁrst
population-based study that looked at the preventive
effect of these four different drugs used individually and
also concomitantly.
The mechanism of OAC prevention is possibly related
to inhibition of cyclo-oxygenase (COX)-2 production.
Elevated levels of COX-2 in oesophageal epithelial cells
have been observed in BO, and noted to increase with
disease progression from BO to OAC.33 In experimental
studies, COX-2 inhibitors inhibited the growth of BO
cells, potentially through suppression of basic ﬁbroblast
growth factor.34 Another study conﬁrmed that the end
product of COX-2 conversion (prostaglandin E2) is
reduced in patients with BO without HGD when using
esomeprazole combined with higher doses (up to
325 mg/day) of cardiovascular aspirin.35
Statins exert antineoplastic properties in several ways. By
inhibition of the 3-hydroxy-3-methylglutanyl coenzyme A
reductase enzyme, subsequent modulation of growth
signal transduction, cellular proliferation and cell death is
achieved, which affects different organs.36 In OAC cells
particularly, statins inhibit cell proliferation and induce
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apoptosis37 and limit the metastatic potential by reducing
intracellular adhesion molecules.38 However, statins also
inhibit COX-2 expression in BO cells.39
Contrasting to other studies, we did not observe a sig-
niﬁcant preventive effect of NSAIDs, low-dose
aspirin and statins with respect to the risk of HGD–
OAC.13–14 24 40 Based on the biological mechanisms,
combined use of statins and NSAIDs or statins with
low-dose aspirin may be expected to result in a greater
risk reduction compared to either drug alone. We did
not observe NSAIDs or low-dose aspirin with statins
combined resulting in a signiﬁcant risk reduction of
OAC. This may be due to several reasons. First, despite
our large BO cohort, the number of identiﬁed cases
was smaller. Although we may have not have identiﬁed
all potential OAC cases from the database, in a case–
control study this is not necessary to obtain unbiased
estimates. However, it limited the power of the study
and resulted in statistically non-signiﬁcant results. For
assessment of concomitant drug exposure, in particular,
we did not reach statistical signiﬁcance due to the lack
of power, though this was not the primary aim of the
study.
Our nesting cohort included all incident BO patients
from the general population, and by matching on dur-
ation since BO diagnosis and excluding patients with
prevalent BO , we removed any effect of selective sur-
vival bias, disease severity41 or time window bias,42 as
those patients with BO with a longer follow-up are more
likely to develop HGD or OAC. By doing so, observing
any spurious associations was avoided. Second, we miti-
gated against immortal time bias43 by deﬁning the
exposure period from BO diagnosis up to matching
date, thus avoiding an overestimation of the preventive
effect. The estimates from our study are likely more gen-
eralisable to the daily clinical practice in the general
population, also including patients with less severe BO,
that is, those with a shorter BO segment. A potential
preventive effect of NSAIDs might therefore only be
observed within selected high-risk subgroups.
Table 2 Exposure characteristics of cases and controls in the UK and the Netherlands
The UK The Netherlands
OAC case Control HGD–OAC case
HGD–OAC
control
N=40 N=656 N=17 N=753
NSAIDs
Exposed—N 11 148 2 102
Mean duration of use in days (SD) 205 (373) 218 (348) 18 (4) 49 (111)
Mean cumulative DDD (SD) 223 (393) 232 (383) 9 (2) 31 (79)
Median duration of use in days (IQR) 40 (20–178) 56 (28–203) 18 (15–20) 15 (10–60)
Median cumulative DDD (IQR) 40 (30–223) 56 (28–208) 9 (7–10) 10 (5–30)
Statins
Exposed—N 12 236 3 123
Mean duration of use in days (SD) 648 (569) 996 (913) 570 (289) 409 (300)
Mean cumulative DDD (SD) 466 (353) 1000 (1258) 560 (191) 383 (331)
Median duration of use in days (IQR) 616 (109–966) 728 (350–1386) 450 (360–900) 330 (180–629)
Median cumulative DDD (IQR) 504 (110–775) 625 (243–1248) 450 (450–780) 270 (158–480)
PPIs
Exposed—N 36 570 10 389
Mean duration of use in days (SD) 1500 (1134) 1071 (978) 615 (462) 442 (372)
Mean cumulative DDD (SD) 1425 (1247) 1060 (1123) 576 (402) 661 (1636)
Median duration of use in days (IQR) 1481 (644–2017) 766 (392–1458) 471 (240–1020) 315 (180–630)
Median cumulative DDD (IQR) 1223 (644–1772) 700 (364–1428) 471 (300–719) 360 (180–840)
SSRIs
Exposed—N 5 50 0 15
Mean duration of use in days (SD) 369 (280) 613 (705) – 743 (669)
Mean cumulative DDD (SD) 366 (283) 843 (1430) – 737 (670)
Median duration of use in days (IQR) 252 (252–504) 381 (90–840) – 600 (180–1740)
Median cumulative DDD (IQR) 252 (252–504) 339 (90–896) – 596 (180–1740)
Low-dose aspirin
Exposed—N 10 173 1 47
Mean duration of use in days (SD) 796 (606) 804 (733) 360 391 (301)
Mean cumulative DDD (SD)* – – –
Median duration of use in days (IQR) 672 (448–1344) 600 (280–1096) 270 (180–540)
Median cumulative DDD (IQR) – –
*Low-dose aspirin (≤325 mg/day) has no DDD value.
DDD, defined daily dose; HGD, high-grade dysplasia; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma;
PPIs, proton pump inhibitors; SSRIs, selective serotonin re-uptake inhibitors.
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Table 3 Risk of OAC and HGD–OAC by drug class by duration on data pooled on patient-level
Exposure
Duration
category
OAC HGD–OAC
OAC
Case
N (%)
OAC
Control
N (%)
ORmatched
(95% CI)
p
Value
ORadjusted*
(95% CI)
p
Value
Case
N (%)
Control
N (%)
ORmatched
(95% CI)
p
Value
ORadjusted*
(95% CI)
p
Value
Total 45 (100) 732 (100) 57 (100) 1409 (100)
NSAID None 32 (71) 566 (77) Ref Ref 44 (77) 1159 (82) Ref Ref
Yes 13 (29) 166 (23) 1.3 (0.6 to 2.5) 0.492 1.2 (0.6 to 2.5) 0.532 13 (23) 250 (18) 1.0 (0.5 to 1.9) 1.000 0.9 (0.5 to 1.8) 0.876
≤1 months 6 (11) 65 (9) 1.4 (0.6 to 3.6) 0.454 1.4 (0.6 to 3.5) 0.471 6 (11) 121 (9) 1.1 (0.4 to 2.6) 0.882 1.0 (0.4 to 2.5) 0.967
>1 months to
1 year
5 (9) 72 (10) 1.2 (0.4 to 3.1) 0.768 1.1 (0.4 to 3.0) 0.817 5 (9) 98 (7) 0.9 (0.3 to 2.4) 0.836 0.8 (0.3 to 2.3) 0.737
>1 year 2 (4) 29 (4) 1.2 (0.3 to 5.3) 0.837 1.1 (0.3 to 5.2) 0.859 2 (4) 31 (2) 1.1 (0.2 to 4.7) 0.934 1.0 (0.2 to 4.6) 0.970
Statins None 33 (73) 479 (65) Ref Ref 42 (74) 1050 (75) Ref Ref
Yes 12 (27) 253 (35) 0.8 (0.4 to 1.5) 0.432 0.7 (0.4 to 1.5) 0.412 15 (26) 359 (25) 0.9 (0.5 to 1.7) 0.720 0.9 (0.5 to 1.7) 0.673
≤1 months 1 (2) 6 (1) 2.1 (0.2 to 20.4) 0.511 2.0 (0.2 to 20.1) 0.561 1 (2) 7 (0) 2.2 (0.2 to 20.6) 0.487 2.1 (0.2 to 20.5) 0.520
>1 months to
1 year
3 (7) 62 (8) 0.9 (0.3 to 3.2) 0.908 1.0 (0.3 to 3.4) 0.971 4 (7) 128 (9) 0.9 (0.3 to 2.8) 0.914 1.0 (0.3 to 2.8) 0.951
>1 to 2 years 4 (9) 66 (9) 0.9 (0.3 to 2.7) 0.848 0.9 (0.3 to 2.6) 0.824 5 (9) 90 (6) 1.1 (0.4 to 2.9) 0.868 1.1 (0.4 to 2.8) 0.907
>2 to 3 years 1 (2) 30 (4) 0.6 (0.1 to 4.9) 0.651 0.6 (0.1 to 4.7) 0.629 2 (4) 41 (3) 1.2 (0.3 to 5.3) 0.828 1.1 (0.2 to 4.9) 0.897
>3 years 3 (7) 89 (12) 0.5 (0.1 to 1.7) 0.259 0.5 (0.1 to 1.7) 0.239 3 (5) 93 (7) 0.5 (0.1 to 1.8) 0.276 0.5 (0.1 to 1.7) 0.253
PPIs 0 to ≤6 months 5 (11) 103 (14) Ref Ref 11 (19) 450 (32) Ref Ref
Yes 40 (89) 629 (86) 1.1 (0.4 to 3.0) 0.814 1.1 (0.4 to 2.8) 0.911 46 (81) 959 (68) 1.0 (0.5 to 2.2) 0.917 0.9 (0.4 to 2.0) 0.855
>6 to
≤12 months
6 (13) 169 (23) 1.9 (0.5 to 6.6) 0.502 2.0 (0.5 to 7.0) 0.299 7 (12) 158 (11) 1.7 (0.6 to 4.6) 0.293 1.7 (0.6 to 4.5) 0.312
>12 to
≤24 months
9 (20) 151 (21) 1.8 (0.6 to 5.4) 0.672 1.7 (0.6 to 5.3) 0.328 10 (18) 227 (16) 1.7 (0.7 to 4.2) 0.255 1.6 (0.6 to 3.9) 0.326
>24 months 5 (11) 162 (22) 2.1 (0.8 to 5.6) 0.476 1.9 (0.7 to 5.2) 0.207 27 (47) 377 (27) 1.7 (0.7 to 4.0) 0.204 1.5 (0.7 to 3.6) 0.327
SSRIs None 40 (89) 679 (93) Ref Ref 52 (91) 1344 (95) Ref Ref
Yes 5 (11) 53 (7) 1.7 (0.6 to 4.7) 0.281 1.7 (0.6 to 4.6) 0.310 5 (9) 65 (5) 1.6 (0.6 to 4.2) 0.356 1.5 (0.6 to 4.1) 0.390
≤1 months 0 (0) 3 (0) – 0.992 – 0.992 0 (0) 3 (0) – 0.988 – 0.988
>1 months to
1 year
3 (7) 23 (3) 2.6 (0.7 to 9.2) 0.142 2.5 (0.7 to 8.9) 0.155 3 (5) 28 (2) 2.4 (0.7 to 8.6) 0.165 2.4 (0.7 to 8.4) 0.175
>1 year 2 (4) 27 (4) 1.2 (0.3 to 5.5) 0.778 1.2 (0.3 to 5.4) 0.815 2 (4) 34 (2) 1.1 (0.2 to 4.9) 0.888 1.1 (0.2 to 4.7) 0.931
Low-dose
aspirin
None 35 (78) 553 (76) Ref Ref 46 (81) 1189 (84) Ref Ref
Yes 10 (22) 179 (24) 0.9 (0.4 to 1.8) 0.702 0.8 (0.4 to 1.8) 0.662 11 (19) 220 (16) 0.9 (0.4 to 1.9) 0.799 0.9 (0.4 to 1.8) 0.764
≤6 months 2 (4) 33 (5) 1.0 (0.2 to 4.2) 0.954 1.0 (0.2 to 4.3) 0.970 2 (4) 49 (3) 0.9 (0.2 to 3.7) 0.840 0.9 (0.2 to 3.8) 0.847
>6 months to
1 year
0 (0) 26 (4) – – 1 (2) 36 (3) – –
>1 year 8 (18) 120 (16) 1.0 (0.4 to 2.2) 0.920 0.9 (0.4 to 2.1) 0.844 8 (14) 135 (10) 0.9 (0.4 to 2.1) 0.867 0.9 (0.4 to 2.1) 0.805
*Adjusted for duration of follow-up since BO diagnosis.
Cumulative use of drugs considered continuously (OR represents the change per day additional use).
BO, Barrett’s oesophagus; HGD, high-grade dysplasia; NSAID, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; OAC, oesophageal adenocarcinoma; SSRIs, selective
serotonin re-uptake inhibitors.
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Table 5 Risk of OAC and HGD–OAC for concomitant drug exposure of NSAIDs, LDA, statins and PPIs
Drug
exposure*
OAC only HGD–OAC
Case
N (%)
Control
N (%)
ORmatched
(95% CI)
p
Value
ORadjusted
model†
(95% CI)
p
Value
Case
N (%)
Control
N (%)
ORmatched
(95% CI)
p
Value
ORadjusted
model† (95% CI)
p
Value
Total 45 (100) 732 (100) 57 (100) 1409 (100)
PPI only 19 (42) 284 (39) Ref – Ref – 22 (39) 441 (31) Ref – Ref –
No NSAID or
LDA or statin or
PPI
3 (7) 65 (9) 0.9 (0.2 to 3.2) 0.837 0.9 (0.3 to 3.4) 0.919 9 (16) 407 (29) 1.0 (0.4 to 2.4) 0.947 1.1 (0.4 to 2.8) 0.839
NSAID+PPI 6 (13) 72 (10) 1.2 (0.5 to 3.2) 0.700 1.1 (0.4 to 3.0) 0.773 6 (11) 124 (9) 0.9 (0.4 to 2.4) 0.898 0.9 (0.3 to 2.2) 0.774
Statin+PPI 5 (11) 85 (12) 1.0 (0.4 to 2.9) 0.963 1.0 (0.3 to 2.8) 0.988 7 (12) 143 (10) 1.2 (0.5 to 3.1) 0.630 1.2 (0.5 to 3.0) 0.674
LDA+PPI 3 (7) 30 (4) 1.4 (0.4 to 5.5) 0.597 1.3 (0.4 to 5.2) 0.655 3 (5) 42 (3) 1.3 (0.4 to 4.9) 0.691 1.2 (0.3 to 4.7) 0.742
LDA+PPI+statin 2 (4) 104 (7) 0.4 (0.1 to 1.7) 0.202 0.4 (0.1 to 1.7) 0.198
NSAID+LDA
+statin+PPI
4 (9) 41 (6) 1.2 (0.4 to 3.8) 0.744 1.2 (0.4 to 3.8) 0.760 4 (7) 43 (3) 1.2 (0.4 to 3.9) 0.727 1.2 (0.4 to 3.8) 0.745
*Numbers do not add up due to drug exposure categories with only one exposed case, not shown in the Table.
†Adjusted for duration of follow-up since BO diagnosis.
BO, Barrett’s oesophagus; HGD, high-grade dysplasia; LDA, low-dose aspirin; NSAID, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma; PPIs, proton pump inhibitors.
Table 4 Risk of OAC and HGD–OAC by drug class by daily dose on data pooled on patient-level
Drug exposure Dose category
OAC only HGD–OAC
Case
N (%)
Control
N (%)
ORmatched
(95% CI) p Value
Case
N (%)
Control
N (%)
ORmatched
(95% CI) p Value
Total 45 (100) 732 (100) 57 (100) 1409 (100)
NSAID None 32 (71) 566 (77) Ref – 44 (77) 1159 (82) Ref –
<0.8 DDD per day 3 (7) 39 (5) 1.1 (0.3 to 3.7) 0.909 3 (5) 107 (8) 0.6 (0.2 to 2.2) 0.475
≥0.8 to <1.2 DDD per day 4 (9) 74 (10) 0.9 (0.3 to 2.5) 0.783 4 (7) 84 (6) 0.8 (0.3 to 2.3) 0.633
≥1.2 DDD per day 6 (13) 53 (7) 2.2 (0.8 to 5.6) 0.111 6 (11) 59 (4) 1.9 (0.8 to 5.0) 0.160
Statin None 33 (73) 479 (65) Ref – 42 (74) 1050 (75) Ref –
<0.8 DDD per day 8 (18) 126 (17) 0.9 (0.4 to 2.2) 0.880 9 (16) 174 (12) 1.0 (0.5 to 2.1) 0.959
≥0.8 to <1.2 DDD per day 1 (2) 49 (7) 0.3 (0.05 to 2.6) 0.305 2 (4) 62 (4) 0.7 (0.2 to 3.1) 0.637
≥1.2 DDD per day 3 (7) 78 (11) 0.7 (0.2 to 2.3) 0.519 4 (7) 123 (9) 0.8 (0.3 to 2.4) 0.731
PPI None 5 (11) 103 (14) Ref – 11 (19) 450 (32) Ref –
<0.8 DDD per day 9 (20) 168 (23) 0.9 (0.3 to 3.0) 0.914 11 (19) 196 (14) 1.1 (0.4 to 2.8) 0.910
≥0.8 to <1.2 DDD per day 23 (51) 315 (43) 1.2 (0.4 to 3.4) 0.723 27 (47) 454 (32) 1.1 (0.5 to 2.6) 0.768
≥1.2 DDD per day 8 (18) 146 (20) 1.1 (0.4 to 3.6) 0.822 8 (14) 309 (22) 0.9 (0.3 to 2.3) 0.813
SSRI None 40 (89) 679 (93) Ref – 52 (91) 1344 (95) Ref –
<0.8 DDD per day 1 (2) 8 (1) 3.0 (0.4 to 25.4) 0.317 1 (2) 8 (1) 3 (0.3 to 25.1) 0.321
≥0.8 to <1.2 DDD per day 4 (9) 32 (4) 2.3 (0.7 to 7.1) 0.149 4 (7) 44 (3) 2.0 (0.7 to 6.0) 0.218
≥1.2 DDD per day 0 (0) 13 (2) – 0.987 0 (0) 13 (1) – 0.987
DDD, defined daily dose; HGD, high-grade dysplasia; NSAID, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma; PPIs, proton pump inhibitors; SSRIs, selective
serotonin re-uptake inhibitors.
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Third, the inability to show a signiﬁcant decrease in
HGD and OAC risk for drug use may be explained by the
distinct exposure deﬁnition that we applied. Contrasting
with others,13 40 we classiﬁed exposure cumulatively and
performed dose–duration analyses rather than assessing
drug exposure at a single moment. This, however, also
limited the analyses by creating multiple exposure categor-
ies. Drug exposure changes over time, especially in the
long time taken to develop cancer. Assessment of exposure
on a ﬁxed moment will result in bias that exaggerates the
effect downwards, showing a protective effect while actu-
ally it has no effect.42 A pooled analysis of observational
studies demonstrated an inverse association between the
risk of HGD–OAC and use of NSAIDs.24 A prospective
cohort study also showed a decreased HR of HGD–OAC
for use of NSAIDs and statins, however, the study results
were inﬂuenced by immortal time bias.17 44 In that study,
the majority of cases included HGD cases. In line with the
other Dutch study,17 when we included HGD cases the risk
of HGD–OAC was lower than when including OAC cases
only. The preventive effect is possibly achieved in the pre-
malignant stage of dysplasia-development rather than that
of adenocarcinoma. It is, however, difﬁcult to disentangle
drug exposure effects in three different risk periods:
induction (dysplasia), latent (between dysplasia and
cancer) and disease period (cancer). Ideally, this requires
knowledge on exact timing of the ﬁrst aberrant Barrett's
cell and subsequent stages towards HGD and OAC pro-
gression develop.
The fourth explanation for not observing a preventive
effect may be the exposure prevalence. Regarding NSAID
exposure prevalence, we could not capture over-the-
counter use of NSAIDs. During the study period, NSAIDs
and PPIs were reimbursable in the NL and the UK, and
thus we assume that over-the-counter use of NSAIDs and
PPIs did not confound the results to a great extent.
Prevalence of PPI (81%) and statin (26%) exposure in our
study is, however, comparable with other studies and is
therefore unlikely to have limited our power.17 45
A large prospective US cohort study showed a tremen-
dous protective effect of NSAIDs on OAC risk.40 However,
NSAID exposure was assessed in a personal interview and
classiﬁed very broadly by NSAIDs used at least once a week
for 6 months.40 If the preventive effect of NSAIDs were as
high as reported (up to 80%), a duration–dose–response
effect is to be expected. This study failed to demonstrate
an inverse association between duration of NSAID use and
the risk of OAC. In fact, the opposite was observed; the
most protective effect was seen for the shortest duration,40
contradicting a causal association.27 46 A pooled analysis
also could not demonstrate that prolonged duration of
NSAID use was associated with a lower risk of OAC.24
Additionally, heterogeneity between studies was
observed,24 which emphasises the controversy around clin-
ically effective chemoprevention with NSAIDs.
The preventive effect of statins is shown in several
studies,13 17 yielding a risk reduction of OAC up to 48%
for statin use >1 year.15 However, in a meta-analysis, the
risk reduction of OAC among patients with BO was only
seen when studies were included that assessed drug
exposure by patient interview, which may be prone to
recall bias, whereas the risk reduction was not signiﬁ-
cant, including studies that assessed drug exposure by
use of prescription/dispensing data in electronic
medical records.26 Also, for statins, the most pro-
nounced effect was seen when HGD was included.16
Results from the latter study should be interpreted with
caution as drug exposure was classiﬁed by self-report as
‘ever’ instead of a duration classiﬁcation. A recent case–
control study, using a GP database from the UK, showed
that statins may also decrease the risk of OAC and oeso-
phagogastric junctional adenocarcinoma in the general
population.47 The chemopreventive action of statins was
more pronounced when combined with low-dose aspirin
in a previous study.13 It could be that the preventive
effect of statins is explained by other risk factors
common to statin users and patients with OAC, such as
cardiovascular risk factors or lifestyle changes: smoking,
exercise and weight.47 Also it may be that patients with
BO died from vascular diseases rather than of cancer-
related causes or before HGD or OAC developed.48 In
our study, statin users were less likely to be current
smokers, were of older age and were more often men.
However, whether lifestyle changes due to comorbid car-
diovascular diseases and initiating statin therapy may
have resulted in healthier behaviour, and subsequent
OAC risk reduction, is open to debate.
Strengths of the current study include the scale and
setting by combining healthcare data from two
European countries with comparable GP databases and
applying a common study protocol and drug exposure
deﬁnition. The nested case–control design in a well-
deﬁned population representing the general population
minimised selection bias. While previous studies may
have suffered from recall bias or the lack of detailed
drug prescription data, we were able to estimate the risk
of HGD and OAC within patients with BO during drug
use in the general population. Although our analysis
may be limited by the small number of cases in the
dose–duration analyses, partly due to the fact that we
only included incident cases (diagnosed ≥1 year after
BO diagnosis), our study is unlikely to suffer from biases
(immortal time bias, time window bias) and confound-
ing (disease severity) by matching on important risk
factors. Matched and adjusted analyses were in line with
each other suggesting that there was little confounding.
A limitation of the study is the lack of detailed path-
ology information on the Barrett segment length and
grade of dysplasia, as is current practice for risk stratiﬁca-
tion of patients with BO. This may have resulted in mis-
classiﬁcation of BO and OAC. However, the 1-year risk of
OAC after BO diagnosis, excluding OAC cases within
1 year after BO diagnosis, was 0.086% (95% CI 0.04 to
0.17) in the current study,10 which is similar to other
population-based studies.4 49 50 Because we could not
verify the diagnosis of BO against a clinical prespeciﬁed
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standard and did not review biopsy specimens, it is also
possible that we inadvertently included patients at very
low risk of developing OAC. In the Dutch database, we
could search through the medical records and noted
that 8% had a segment length <2 cm, 13.7% between 2
and 3 cm, 11.8% longer than 3 cm, whereas for 60% of
BO controls the length was not mentioned. Regarding
the grade of dysplasia at time of BO diagnosis, 45% of
controls had no dysplasia; there was low grade dysplasia
in 6% of patients with BO, indeﬁnite for dysplasia in
1.8%, whereas no information on dysplasia grade was
available in 46% of controls. Of the cases that developed
HGD or OAC, 24% had a prior histology report of low-
grade dysplasia. In the Dutch database we could utilise
all free text entered in the medical record, enabling us
to look for more detailed information in clinical letters,
resulting in higher proportion of risk factors, such as
presence of oesophagitis and a hiatal hernia at time of
BO diagnosis as compared with the UK database, in
which we relied on diagnosis codes. We tried to address
confounding-by-indication and time-window bias by
matching on age, sex and year of BO diagnosis.42 This is
seen by the fact that individual risk factors did not
increase the OAC risk and adjustment for these con-
founders did not change the estimate by ≥10%. The
observation that PPIs appear to increase the risk of OAC
is explained by the treatment indication being a risk
factor for OAC, reverse causation and the phenomenon
of ‘channeling’, where high-risk patients are being
prescribed PPIs whereas low-risk patients are being
prescribed with lower doses or not at all,15 22 47 51 52
a phenomenon often seen with PPIs and upper gastro-
intestinal bleeding.53 It could also be that the effect of
PPIs is apparent after minimally 2 years of use,15 20 an
observation that was not signiﬁcant in our study.
In conclusion, in this population-based nested case–
control study, use of NSAIDs, PPIs, low-dose aspirin or
statins did not reduce the risk of HGD and OAC among
patients with BO. These ﬁndings indicate that for an
unselected group of patients with BO, chemoprevention
by use of drug to reduce progression should not be con-
sidered directly as routine care.
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